ACEI attenuates the progression of CCI4-induced rat hepatic fibrogenesis by inhibiting TGF-β1, PDGF-BB, NF-κB and MMP-2,9

World Journal of Gastroenterology

Volumn 11, Issue 31, 2005, Pages 4807-4811

  Li, Xu ^a   Meng, Ying ^a   Yang, Xi Shan ^a   Mi, Ling Fei ^b   Cai, Shao Xi ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b First People's Hospital of Huaihua   (China)

Author keywords

Angiotensin converting enzyme inhibitor; Hepatic fibrosis; Renin angiotensin aldosterone system

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANTIFIBROTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE A; GELATINASE B; HYALURONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAMININ; OLIVE OIL; PERINDOPRIL; PLATELET DERIVED GROWTH FACTOR BB; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DNA BINDING; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; GEL MOBILITY SHIFT ASSAY; LIVER FIBROSIS; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RADIOIMMUNOASSAY; RAT; RAT STRAIN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SCORING SYSTEM; TISSUE DISTRIBUTION; TISSUE SECTION; TREATMENT OUTCOME; UPREGULATION; WESTERN BLOTTING; ZYMOGRAPHY;

EID: 24044494889     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i31.4807     Document Type: Article

References (27)

1. Asbert M, Jimenez W, Gaya J, Gines P, Arroyo V, Rivera F, Rodes J. Assessment of the renin-angiotensin system in cirrhotic patients. Comparison between plasma renin activity and direct measurement of immunoreactive renin. J Hepatol 1992; 15: 179-183
2. Paizis G, Cooper ME, Schembri JM, Tikellis C, Burrell LM, Angus PW. Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology 2002; 123: 1667-1676
3. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, Purdie DM, Jonsson JR. Host genetic factors influence disease progression in chronic hepatic C. Hepatology 2000; 31: 828-833
4. Ramalho LN, Ramalho FS, Zucoloto S, Castro-e-Silva Junior O, Correa FM, Elias Junior J, Magalhaes JF. Effect of losartan, an angiotensin II antagonist, on secondary biliary cirrhosis. Hepatogastroenterology 2002; 49: 1499-1502
5. Paizis G, Gilbert RE, Cooper ME, Murthi P, Schembri JM, Wu LL, Rumble JR, Kelly DJ, Tikellis C, Cox A, Smallwood RA, Angus PW. Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol 2001; 35: 376-385
6. Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani T, Imazu H, Yanase K, Kuriyama S, Fukui H. Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. J Hepatol 2002; 37: 22-30
7. Croquet V, Moal F, Veal N, Wang J, Oberti F, Roux J, Vuillemin E, Gallois Y, Douay O, Chappard D, Cales P. Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension. J Hepatol 2002; 37: 773-780
8. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-374
9. Campbell SE, Katwa LC. Angiotensin II stimulated expression of transforming growth factor-beta1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol 1997; 29: 1947-1958
10. Marshall RP, Mcanulty RJ, Laurent GJ. Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor. Am J Respir Crit Care Med 2000; 161: 1999-2004
11. Yokota S, Tsuji H, Kato K. Localization of cathepsin D in rat liver. Immunocytochemical study using post-embedding immunoenzyme and protein A-gold techniques. Histochemistry 1985; 82: 141-148
12. Klickstein LB, Kaempfer CE, Wintroub BU. The granulocyte-angiotensin system. Angiotensin I-converting activity of cathepsin G. J Biol Chem 1982; 257: 15042-15046
13. Bataller R, Gines P, Nicolas JM, Gorbig MN, Garcia-Ramallo E, Gasull X, Bosch J, Arroyo V, Rodes J. Angiotensin ¢ ̀induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000; 118: 1149-1156
14. Li X, Meng Y, Yang XS, Wu PS, Li SM, Lai WY. CYP11B2 expression in HSCs and its effect on hepatic fibrogenesis. World J Gastroenterol 2000; 6: 885-887
15. Yang X, Li X, Wu P, Meng Y, Li S, Lai W. CYP11B2 expression in rat liver and the effect of spironolactone on hepatic fibrogenesis. Horm Res 2000; 53: 288-293
16. Li X, Yang XS, Wu PS, Li SM, Lai WY. Gene-CYP11B2 expression in rat liver in hepatic fibrogenesis induced by CC14. Chin Med J 2001; 114: 64-68
17. Kim S, Zhan Y, Izumi Y, Yano M, Iwao H. In vivo activation of rat aortic platelet-derived growth factor and epidermal growth factor receptors by angiotensin II and hypertension. Arterioscler Thromb Vasc Biol 2000; 20: 2539-2545
18. Hamaguchi A, Kim S, Izumi Y, Zhan Y, Yamanaka S, Iwao H. Contribution of extracellular signal-regulated kinase to angiotensin II-induced transforming growth factor-beta1 expression in vascular smooth muscle cells. Hypertension 1999; 34: 126-131
19. Hellerbrand C, Jobin C, Licato LL, Sartor RB, Brenner DA. Cytokines induce NF-kappa B in activated but not in quiescent rat hepatic stellate cells. Am J Physiol 1998; 275: G269-278
20. Lang A, Schoonhovan R, Tuvia S, Brenner DA, Rippe RA. Nuclear factor kappa B in proliferation, activation and apoptosis in rat hepatic stellate cells. J Hepatol 2000; 33: 49-58
21. Taub R. Blocking NF-kappa B in the liver: the good and bad news. Hepatology 1998; 27: 1445-1446
22. Shakhov AN, Collart MA, Vassalli P, Nedospasov SA, Jongeneel CV. Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. Exp Med 1990; 171: 35-47
23. Collart MA, Baeuerle P, Vassalli P. Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B. Mol Cell Biol 1990; 10: 1498-1506
24. Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999; 18: 6853-6866
25. Sorbi D, Fadly M, Hicks R, Alexander S, Arbeit L. Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases. Kidney Int 1993; 44: 1266-1272
26. Philip S, Bulbule A, Kundu GC. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-κB-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem 2001; 276: 44926-44935
27. Jonsson JR, Clouston AD, Ando Y, Kelemen LI, Horn MJ, Adamson MD, Purdie DM, Powell EE. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 2001; 121: 148-155